RibbonLetters homepage

A special issue on HIV vaccine science in Africa, for Africa

There is an unbridled sense of optimism in the HIV prevention field today. There are now two vaccine efficacy trials and an efficacy study of antibodies for HIV prevention ongoing, all of them in Africa. There is also a new generation of HIV vaccine candidates entering clinical trials. These candidates harness the tremendous insights into natural infection and the development of broadly neutralizing antibodies that have been garnered during the last decade. There is also significant progress on another front—the increasingly prominent role African scientists are playing in the quest to develop an HIV vaccine. Much of this progress is the result of a sustained effort by IAVI, through its decades-long partnership with the U.S. Agency for International Development (USAID), to nurture scientific talent on the African continent. That is the theme of this issue. It is the first issue of IAVI Report we’ve ever dedicated to a single topic, and it is an important one.